Filtered By:
Source: Vaccine
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 25 results found since Jan 2013.
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
CONCLUSIONS: Safety and immunogenicity of coadministered PCV20 and BNT162b2 were similar to those of PCV20 or BNT162b2 administered alone, suggesting that the 2 vaccines may be coadministered.TRIAL REGISTRATION: ClinicalTrials.gov, NCT04887948.PMID:37244809 | PMC:PMC10165018 | DOI:10.1016/j.vaccine.2023.05.002
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: David Fitz-Patrick Mariano Young Kari Yacisin Kathleen McElwee Todd Belanger Kelly Belanger Yahong Peng Dung-Yang Lee William C Gruber Daniel A Scott Wendy Watson Source Type: research
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial
CONCLUSIONS: Immune responses after coadministration of PCV20 and QIV were noninferior to separate administration of either vaccine. The PCV20 safety profile was similar when given together with or after QIV. These findings support PCV20 and QIV coadministration.TRIAL REGISTRATION: ClinicalTrials.gov, NCT04526574.PMID:36828719 | DOI:10.1016/j.vaccine.2022.11.046
Source: Vaccine - February 24, 2023 Category: Allergy & Immunology Authors: Kevin Cannon Jose F Cardona Kari Yacisin Allison Thompson Todd J Belanger Dung-Yang Lee Yahong Peng Lisa Moyer John Ginis William C Gruber Daniel A Scott Wendy Watson Source Type: research
Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine
CONCLUSION: Extensive data derived from clinical trials and postmarketing experience indicate a consistently favorable safety profile for MenACWY-TT across a wide range of age groups.PMID:36283896 | DOI:10.1016/j.vaccine.2022.09.077
Source: Vaccine - October 25, 2022 Category: Allergy & Immunology Authors: Lidia Serra Chris Webber Cindy Burman Patrizia Bueti Maria Gorruso Susan Mather Source Type: research
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years
CONCLUSIONS: These results demonstrate that ASP3772 is well tolerated, highly immunogenic, and in adults may offer significantly broader protection than existing pneumococcal vaccines.CLINICALTRIALS: gov: NCT03803202.PMID:35690500 | DOI:10.1016/j.vaccine.2022.05.079
Source: Vaccine - June 11, 2022 Category: Allergy & Immunology Authors: Gurunadh R Chichili Ronald Smulders Vicki Santos Beth Cywin Laura Kovanda Charles Van Sant Frank Malinoski Shite Sebastian George Siber Richard Malley Source Type: research
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)
CONCLUSIONS: V114 is well tolerated with a consistent safety profile and immune response across manufacturing lots.CLINICAL TRIALS REGISTRATION: NCT03950856 (www.clinicaltrials.gov); 2018-004266-33 (EudraCT).PMID:35039194 | DOI:10.1016/j.vaccine.2021.12.067
Source: Vaccine - January 18, 2022 Category: Allergy & Immunology Authors: Jakub K Simon Nina Breinholt Staerke Maria Hemming-Harlo Stacey Layle Ron Dagan Tulin Shekar Alison Pedley Patricia Jumes Gretchen Tamms Tina Sterling Luwy Musey Ulrike K Buchwald V114-020 PNEU-TRUE study group Source Type: research
Safety surveillance of meningococcal group B vaccine (Bexsero ®), Vaccine Adverse Event Reporting System, 2015-2018
CONCLUSIONS: Analysis of passive surveillance data from over 5.6 million doses of MenB-4C distributed in the United States did not reveal new safety concerns. The large majority of reports were classified as non-serious and the reported AEs were generally consistent with the safety experience described in clinical studies and the product's package insert. While our results are reassuring, continued post-marketing surveillance is warranted.PMID:34887130 | DOI:10.1016/j.vaccine.2021.11.071
Source: Vaccine - December 10, 2021 Category: Allergy & Immunology Authors: Silvia Perez-Vilar Gra ça M Dores Paige L Marquez Carmen S Ng Maria V Cano Anuja Rastogi Lucia Lee John R Su Jonathan Duffy Source Type: research
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)
Vaccine. 2021 Sep 7:S0264-410X(21)01097-5. doi: 10.1016/j.vaccine.2021.08.049. Online ahead of print.ABSTRACTBACKGROUND: Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) is a 15-valent PCV containing 13 serotypes in licensed PCV13 and 2 additional serotypes (22F, 33F) which significantly contribute to pneumococcal disease burden. This phase 3 trial compared safety, toler...
Source: Vaccine - September 11, 2021 Category: Allergy & Immunology Authors: Heather L Platt Jose F Cardona Miwa Haranaka Howard I Schwartz Silvia Narejos Perez Anthony Dowell Chih-Jen Chang Ron Dagan Gretchen M Tamms Tina Sterling Leslie Morgan Yaru Shi Alison Pedley Luwy K Musey Ulrike K Buchwald Source Type: research
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
CONCLUSION: Administration of V114 followed by PPSV23 was well tolerated and induced comparable antibody levels to PCV13 followed by PPSV23 in healthy adults aged ≥50 years.PMID:34489128 | DOI:10.1016/j.vaccine.2021.08.038
Source: Vaccine - September 7, 2021 Category: Allergy & Immunology Authors: Joon-Young Song Chih-Jen Chang Charles Andrews Javier Diez-Domingo Myoung-Don Oh Ron Dagan Jonathan Hartzel Alison Pedley Jianing Li Tina Sterling Gretchen Tamms Joseph A Chiarappa Jeannine Lutkiewicz Luwy Musey Yingmei Tu Ulrike K Buchwald V114-016 (PNEU Source Type: research
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India
CONCLUSION: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneumococcal disease in this age group in India.PMID:34366142 | DOI:10.1016/j.vaccine.2021.07.055
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: Jugesh Chhatwal Amita Sapru Balasubramanian Sundaram Bhaskar Shenoy Rohit Chand Kevin Yi Suresh Suroju Daniel A Scott Stephen Lockhart Source Type: research
